CIK 0001640266
- Accelerated filer
- Smaller reporting company
Voyager Therapeutics, Inc.
Sign in to watch- Ticker
- VYGR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 857-259-5340
- Business address
- 75 HAYDEN AVENUE, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-01 | Carter Todd Alfred Chief Scientific Officer | Grant or award | +33,000 | 178,718 | ||
| 2026-11-01 | Carter Todd Alfred Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +154,000 | 154,000 | ||
| 2026-11-01 | Swartz Robin President | Grant or award | +68,250 | 267,988 | ||
| 2026-11-01 | Swartz Robin President | Grant or award · Stock Option (Right to Buy) | +318,500 | 318,500 | ||
| 2026-06-09 | SCANGOS GEORGE A Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2026-06-09 | MACKEY CATHERINE J Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2026-06-09 | Hyman Steven Director | Grant or award · Stock Option (Right to Buy) | +30,000 | |||
| 2026-06-09 | Vitale Nancy Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2026-06-09 | Higgins Michael J Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2026-06-09 | Onyia Jude Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2026-06-09 | GERAGHTY JAMES A Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2026-06-09 | Colon Grace Director | Grant or award · Stock Option (Right to Buy) | +30,000 | |||
| 2026-06-09 | PIERCE GLENN Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2026-04-02 | Sandrock Alfred President and CEO | Sale 10b5-1 | −11,511 | $3.87 | $45K | 472,549 |
| 2026-04-01 | Shiferman Gregory L. SVP and General Counsel | Grant or award | +50,000 | 50,000 | ||
| 2026-02-24 | Swartz Robin COO & CBO | Sale 10b5-1 | −6,458 | $3.77 | $24K | 199,738 |
| 2026-02-24 | Sandrock Alfred President and CEO | Sale 10b5-1 | −14,197 | $3.79 | $54K | 484,060 |
| 2026-02-24 | Jorgensen Nathan D. Chief Financial Officer | Sale 10b5-1 | −4,668 | $3.77 | $18K | 151,416 |
| 2026-02-24 | Carter Todd Alfred Chief Scientific Officer | Sale 10b5-1 | −4,174 | $3.76 | $16K | 145,718 |
| 2026-02-18 | Swartz Robin COO & CBO | Sale 10b5-1 | −3,882 | $3.44 | $13K | 206,196 |
Page 1 of 7 · 130 trades